Eli Lilly & Co. is escalating its legal and regulatory offensive against an illegal market for retatrutide, an experimental weight-loss drug that has never been approved by regulators anywhere in the world. The company has filed a handful of lawsuits against U.S. businesses — many based in Texas — that sell retatrutide products illegally, citing customer complaints and social media advertisements as evidence.
The scale of the problem is striking. Lilly says it has reported more than 14,000 websites, advertisements, social media posts and product listings across more than 100 countries, and has referred more than 200 entities to the FDA, the U.S. Department of Justice, state attorneys general, law enforcement and professional licensing boards. Despite that effort, a Bloomberg analysis found that as of Aug. 11, many companies that had received FDA warning letters since 2024 were still offering knockoff versions.
'It's a huge problem, a global problem,' said Max Denning, an associate vice president at Lilly who oversees global patient safety for its cardiometabolic health division. 'It's not something we can tackle alone.' Denning described the enforcement challenge as a game of 'whack-a-mole,' with products frequently manufactured by unregulated foreign suppliers.
One business cited in the lawsuits offered a calculator to help consumers determine their own retatrutide dosage — a function that is typically performed by a licensed physician. Lilly is also calling on credit card companies, shipping firms and social media platforms to cut off the supply chain, framing the situation as an 'urgent public health crisis.'
The FDA has stated it is illegal for pharmacies to compound retatrutide and has urged consumers 'not to use retatrutide unless they are part of a clinical trial.' The agency noted that 'compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality.' On social media, the drug circulates under nicknames including 'reta,' 'r3ta' and even 'ratatouille' — workarounds designed to evade platform restrictions on weight-loss content.
The financial stakes are considerable. If approved, retatrutide is expected to generate more than $5.4 billion in annual sales for Lilly by 2030. The company plans to seek FDA approval early next year. Any safety incident tied to a counterfeit version could damage the drug's reputation before it ever reaches the legal market — a risk that makes the enforcement campaign as much a business imperative as a public health one.
There have been some enforcement wins. Federal prosecutors have been targeting illegal sellers, and last month a judge sentenced the owner of a popular peptide company that sold retatrutide to nearly six years in prison. A large Customs and Border Protection seizure in Cincinnati last year was also cited by Lilly as 'encouraging.' The company says it is now engaging law enforcement in the UK, Brazil, New Zealand, Saudi Arabia and Hong Kong.
The numbers come first — and here they point in one direction. When a single drug commands a black market spanning more than 100 countries before it has cleared a single regulatory body, the case for faster, coordinated approval processes becomes hard to dismiss. Regulatory delay does not eliminate demand; it redirects it underground, where there is no quality control, no liability and no recourse for the consumer. Free enterprise works when the rules are clear and enforced. The retatrutide black market is what happens when they are neither.
